by According to the latest research study, the demand of global telecare market size & share was valued at approximately USD 3.7 billion in 2021 and is projected to reach a value of around USD 6.2 billion by 2030, at a compound annual growth rate (CAGR) of about 5.6% during the forecast period 2022 to 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/39191
Growth Factors
Increasing advancement of the technology to provide more efficient and improved healthcare services to patients in their own homes by reducing the costly residence care or clinic attendance is anticipated to drive the market over the forecast years. In addition, growing awareness to maintain physical health and increasing penetration of the internet and smartphones also accelerate market growth. Moreover, increasing adoption and use of consumer-oriented fitness and health apps, exercise tracking tools and sensors, digital medication reminder systems, or early warning and detection technologies that connect people with family members or other caregivers also support the growth of the market.
The growing number of mobile subscribers and increasing penetration of the internet all over the globe are the major factors accelerating the adoption of telecare services. For instance, according to Ericsson, which is a leading provider of information and communication technology there are 8.1 billion mobile subscribers in 2021 and the number will rise to 8.9 billion in 2027.
The increasing number of geriatric population and growing preference to adopt smart remote assistants or personal alarms to monitor unusual behavior patterns or any warning signs of falls for the elderly are among the major factors anticipated to drive the segment growth over the forecast years. In addition, a growing number of telecare centers monitoring the social and lifestyle activity of a physically disabled or elderly individual 24/7 and providing appropriate help such as remote medical assistance is further supporting the growth of the market.
Report Coverage
| Report Scope | Details |
| Market Size | US$ 6.2 billion by 2030 |
| Growth Rate | CAGR of 5.6% From 2022 to 2030 |
| Largest Market | North America |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Type |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Teladoc Health, Inc.; Abbott Laboratories; Johnson and Johnson; AstraZeneca PLC; F. Hoffmann-La Roche Ltd.; Novartis AG; Bristol-Myers Squibb Company; GlaxoSmithKline plc; Merck and Co., Inc.; Pfizer, Inc.; Sanofi; Qualcomm Technologies, Inc.; Orange; Google (Alphabet), Inc.; Allscripts; Airstrip Technologies, Inc.; AT&T; Apple, Inc |
By Type Analysis
The activity monitoring segment dominated the market for telecare and accounted for the highest revenue share of 51.3% in 2021. This high share is attributed due to the high adoption of telecare services for activity monitoring, especially among the elderly population.
The increasing adoption of telecare platforms by patients with physical disabilities for daily activity monitoring and the rising geriatric population to maintain their self-efficacy and remain safe in their own homes are the other factors supporting the growth of the segment.
The remote medication management segment is anticipated to witness the highest CAGR in the market for telecare over the forecast period. Growing demand for management of chronic disease conditions through virtual face-to-face encounters.
By Regional Analysis
North America dominated the telecare market for telecare and accounted for the highest revenue share of 50.5% in 2021. This is attributed to several factors such as the high penetration of smartphones and the internet, growing awareness among individuals to maintain physical health and the use of remote healthcare services.
Asia Pacific, the market for telecare is expected to exhibit the fastest growth rate over the forecast period owing to the large population and increasing demand for remote health management services.
Key Players
- Teladoc Health, Inc.
- Abbott Laboratories
- Johnson and Johnson
- AstraZeneca PLC
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Bristol-Myers Squibb Company
- GlaxoSmithKline plc
- Merck and Co., Inc.
- Pfizer, Inc.
- Sanofi
- Samsung Electronics Co. Ltd
- Qualcomm Technologies, Inc.
- Orange
- Google (Alphabet), Inc
- Allscripts
- Airstrip Technologies, Inc
- AT&T
- Apple, Inc.
Market Segmentation
- By Product
- Activity Monitoring
- Remote Medication Management
- Regional
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Asia Pacific
- Australia
- China
- Japan
- South Korea
- India
- Singapore
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East Africa
- South Africa
- Saudi Arabia
- UAE
- North America
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Telecare Market, By Product Type
7.1. Telecare Market, by Product Type, 2021-2030
7.1.1. Activity Monitoring
7.1.1.1. Market Revenue and Forecast (2019-2030)
7.1.2. Remote Medication Management
7.1.2.1. Market Revenue and Forecast (2019-2030)
Chapter 8. Global Telecare Market, Regional Estimates and Trend Forecast
8.1. North America
8.1.1. Market Revenue and Forecast, by Product Type (2019-2030)
8.1.2. U.S.
8.1.3. Rest of North America
8.1.3.1. Market Revenue and Forecast, by Product Type (2019-2030)
8.2. Europe
8.2.1. Market Revenue and Forecast, by Product Type (2019-2030)
8.2.2. UK
8.2.2.1. Market Revenue and Forecast, by Product Type (2019-2030)
8.2.3. France
8.2.3.1. Market Revenue and Forecast, by Product Type (2019-2030)
8.2.4. Rest of Europe
8.2.4.1. Market Revenue and Forecast, by Product Type (2019-2030)
8.3. APAC
8.3.1. Market Revenue and Forecast, by Product Type (2019-2030)
8.3.2. India
8.3.2.1. Market Revenue and Forecast, by Product Type (2019-2030)
8.3.3. China
8.3.3.1. Market Revenue and Forecast, by Product Type (2019-2030)
8.3.4. Japan
8.3.4.1. Market Revenue and Forecast, by Product Type (2019-2030)
8.3.5. Rest of APAC
8.3.5.1. Market Revenue and Forecast, by Product Type (2019-2030)
8.4. MEA
8.4.1. Market Revenue and Forecast, by Product Type (2019-2030)
8.4.2. GCC
8.4.2.1. Market Revenue and Forecast, by Product Type (2019-2030)
8.4.3. North Africa
8.4.3.1. Market Revenue and Forecast, by Product Type (2019-2030)
8.4.4. South Africa
8.4.4.1. Market Revenue and Forecast, by Product Type (2019-2030)
8.4.5. Rest of MEA
8.4.5.1. Market Revenue and Forecast, by Product Type (2019-2030)
8.5. Latin America
8.5.1. Market Revenue and Forecast, by Product Type (2019-2030)
8.5.2. Brazil
8.5.2.1. Market Revenue and Forecast, by Product Type (2019-2030)
8.5.3. Rest of LATAM
8.5.3.1. Market Revenue and Forecast, by Product Type (2019-2030)
Chapter 9. Company Profiles
9.1. Teladoc Health, Inc.
9.1.1. Company Overview
9.1.2. Product Offerings
9.1.3. Financial Performance
9.1.4. Recent Initiatives
9.2. Abbott Laboratories
9.2.1. Company Overview
9.2.2. Product Offerings
9.2.3. Financial Performance
9.2.4. Recent Initiatives
9.3. Johnson and Johnson
9.3.1. Company Overview
9.3.2. Product Offerings
9.3.3. Financial Performance
9.3.4. Recent Initiatives
9.4. AstraZeneca PLC
9.4.1. Company Overview
9.4.2. Product Offerings
9.4.3. Financial Performance
9.4.4. Recent Initiatives
9.5. F. Hoffmann-La Roche Ltd.
9.5.1. Company Overview
9.5.2. Product Offerings
9.5.3. Financial Performance
9.5.4. Recent Initiatives
9.6. Novartis AG
9.6.1. Company Overview
9.6.2. Product Offerings
9.6.3. Financial Performance
9.6.4. Recent Initiatives
9.7. Bristol-Myers Squibb Company
9.7.1. Company Overview
9.7.2. Product Offerings
9.7.3. Financial Performance
9.7.4. Recent Initiatives
9.8. GlaxoSmithKline plc
9.8.1. Company Overview
9.8.2. Product Offerings
9.8.3. Financial Performance
9.8.4. Recent Initiatives
Chapter 10. Research Methodology
10.1. Primary Research
10.2. Secondary Research
10.3. Assumptions
Chapter 11. Appendix
11.1. About Us
11.2. Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39191
Contact Us:
Vision Research Reports
Call: +1 9197 992 333
